Oracle
ORCL
Amazon
AMZN
Alphabet-A
GOOGL
Apple
AAPL
Meta Platforms
META
US Stock MarketDetailed Quotes
ENSC Ensysce Biosciences
- 6.2697
- +0.1997+3.29%
Trading Dec 19 12:13 ET
8.18MMarket Cap-0.22P/E (TTM)
6.4794High5.9700Low37.47KVolume6.1800Open6.0700Pre Close231.31KTurnover3.88%Turnover RatioLossP/E (Static)1.30MShares30.900052wk High1.18P/B6.05MFloat Cap2.118052wk Low--Dividend TTM965.13KShs Float86364.0000Historical High--Div YieldTTM8.39%Amplitude2.1150Historical Low6.1730Avg Price1Lot Size
About Ensysce Biosciences Company
Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of solutions for severe pain relief while reducing the fear of and the potential for misuse and overdose. The firm's Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms are in the process of developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. The company was founded in April 2003 and is headquartered in La Jolla, CA.
Company Profile
SymbolENSC
Company NameEnsysce Biosciences
Listing DateDec 29, 2017
Founded2003
CEODr. D. Lynn Kirkpatrick, PhD
MarketNASDAQ
Employees9
Fiscal Year Ends12-31
Address7946 Ivanhoe Avenue,Suite 201
CityLa Jolla
ProvinceCalifornia
CountryUnited States of America
Zip Code92037
Phone1-858-263-4196
Websitehttp://www.ensysce.com
Company Executives
- Name
- Position
- Salary
- Dr. D. Lynn Kirkpatrick, PhD
- President, Chief Executive Officer and Director
- 508.58K
- Dr. Jeffrey Millard, PhD
- Chief Operating Officer
- --
- Linda Pestano, PhD
- Chief Development Officer
- --
- Geoffrey Birkett
- Chief Commercial Officer
- 392.35K
- Dr. William K. Schmidt, PhD
- Chief Medical Officer
- --
- David Humphrey, C.P.A.
- Chief Financial Officer, Principal Accounting Officer, Secretary and Treasurer
- 441.95K
- Dr. Bob G. Gower, PhD
- Chairman of the Board
- 47.60K
- Dr. Curtis Rosebraugh, M.D.
- Independent Director
- 25.42K
- Andrew Benton, J.D.
- Independent Director
- 30.10K
- Dr. Adam S. Levin, M.D.
- Independent Director
- 27.92K
- Lee Rauch
- Independent Director
- 29.17K
- William Chang
- Independent Director
- 30.10K
- Steve R. Martin
- Independent Director
- 32.92K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.